Detalhe da pesquisa
1.
The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trial.
Pharmacogenomics J
; 23(6): 169-177, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37689822
2.
Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee.
Genet Med
; 21(2): 382-390, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29858578
3.
Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.
Antimicrob Agents Chemother
; 60(11): 6813-6822, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27600044
4.
Response to Gammal et al.
Genet Med
; 21(8): 1888-1889, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30635623
5.
Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers.
Curr Ther Res Clin Exp
; 76: 64-9, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25352936
6.
Association of QT interval-prolonging drugs with clinical trial eligibility in patients with advanced cancer.
Front Cardiovasc Med
; 9: 894623, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36588548
7.
Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid Cancers.
JCO Precis Oncol
; 6: e2100312, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35201852
8.
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.
Clin Pharmacol Ther
; 109(2): 302-309, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32779747
9.
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.
Clin Pharmacol Ther
; 110(4): 888-896, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33387367
10.
PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.
Pharmacogenet Genomics
; 24(9): 464-76, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24915143
11.
A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Clin Cancer Res
; 9(15): 5540-9, 2003 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-14654534
12.
The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.
J Clin Pharmacol
; 43(5): 443-69, 2003 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12751267
13.
The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity.
Br J Clin Pharmacol
; 53(1): 67-74, 2002 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-11849197
14.
The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.
Drug Metab Dispos
; 31(7): 815-32, 2003 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-12814957